{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psoriasis/prescribing-information/vitamin-d-preparations/","result":{"pageContext":{"chapter":{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations","depth":2,"htmlHeader":"<!-- begin field 8108944d-4360-4bf9-a71d-e9e7d1590e7c --><h2>Vitamin D preparations</h2><!-- end field 8108944d-4360-4bf9-a71d-e9e7d1590e7c -->","summary":"","htmlStringContent":"<!-- begin item a36be1f2-6ae3-4fd1-90f8-28f9f1f26f0e --><!-- end item a36be1f2-6ae3-4fd1-90f8-28f9f1f26f0e -->","topic":{"id":"a3ecec3a-acde-5ece-90b0-dedc6c08db8b","topicId":"c8702cb0-6f30-44e4-832b-ab9161ee384a","topicName":"Psoriasis","slug":"psoriasis","lastRevised":"Last revised in December 2020","chapters":[{"id":"d0c39045-d8df-5a7e-bd7d-96fef3aefc3a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6e22adaa-de33-5d1c-bc1f-9740d238c5a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a7c9da10-9760-5143-bf20-167f1e832103","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes"},{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update"}]},{"id":"ca38cddf-4680-5dc4-a0df-79ab9910a789","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fc350387-9e56-5f4b-b454-3cfa5ecd9a2a","slug":"goals","fullItemName":"Goals"},{"id":"00a9f2b3-e7b5-5394-9762-48d34a0dc722","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"400cbb71-cb76-5ee3-824a-738bc6249b3b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ad046045-038c-5b75-8f42-50343d5b824e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"773d3740-99b6-5a32-b555-968b2efb0b8b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0692cf2f-4b3d-5098-afe3-ac07b3c763ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d16fcd88-1021-5238-86e4-2452eee7fdde","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ef476810-392e-5b83-b527-fe921221cc0b","slug":"definition","fullItemName":"Definition"},{"id":"fb1e0af3-fd46-562a-83d6-33a31640b639","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d6b8dab4-762f-5e9e-a83e-35a3652483b3","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"70837c8d-73ae-5bc4-a042-949d31503ca3","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"e90f3736-0e28-53fa-8295-309df8aa8e00","slug":"complications","fullItemName":"Complications"},{"id":"9523ad16-6e73-50ba-94bd-64c548f5c313","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment"},{"id":"58b4da96-dda6-596b-9570-fd5070898cfe","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"27af05e5-54bf-5bc5-ba76-d1b8f18e7252","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","fullItemName":"Management","slug":"management","subChapters":[{"id":"82ee7501-0589-54c2-8df7-5a9256a3f1d0","slug":"pustular-or-erythrodermic-psoriasis","fullItemName":"Scenario: Pustular or erythrodermic psoriasis"},{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs"},{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis"},{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis"},{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis"},{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis"},{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ce3be64b-a968-59e2-b206-5a055de98330","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients"},{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations"},{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid"},{"id":"325d4c77-192a-5152-971f-a5f4f1d64fc7","slug":"coal-tar-products","fullItemName":"Coal tar products"},{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)"}]},{"id":"00678b76-cc05-5d69-a6be-8760727fb9cf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91ae130b-06c7-538c-a295-af4bf7a3dbf1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"358d84df-224b-5d6b-96cd-c52dfe00a200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"383c93f2-ae1f-5c75-af43-3a9a448c1669","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3703e9fb-0103-5fe6-a0ed-192226578ed6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d248a57f-2b73-5c2f-89c5-18ed618c3535","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e35fcef8-37a3-5afe-9250-f527d2c6e017","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7314bc52-4cb9-530c-a905-917edad0de05","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ce3be64b-a968-59e2-b206-5a055de98330","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"da193bfb-73a7-5515-9757-c6459b815788","slug":"availability-choice","fullItemName":"Availability and choice","depth":3,"htmlHeader":"<!-- begin field 224d2fe7-95c2-4780-8780-86979df427f6 --><h3>Availability and choice</h3><!-- end field 224d2fe7-95c2-4780-8780-86979df427f6 -->","summary":"","htmlStringContent":"<!-- begin item 9598fe2c-f89a-46aa-bfd9-781794b47820 --><!-- begin field 436fd7ad-362c-4ca8-9114-62064506066a --><ul><li>Topical vitamin D preparations are available as ointments, gels, scalp solutions, and lotions.</li><li>Three vitamin D preparations are available on prescription in the UK:<ul><li>Calcipotriol (Dovonex<sup>®</sup>) — available as an ointment.</li><li>Calcipotriol (non-branded) — available as an ointment and scalp solution.</li><li>Calcitriol (Silkis<sup>®</sup>) — available as an ointment.</li><li>Tacalcitol (Curatoderm<sup>®</sup>) — available as an ointment or lotion.</li><li>Note: calcitriol and tacalcitol may be less irritating than calcipotriol.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">BNF 73, 2017</a>] </p><!-- end field 436fd7ad-362c-4ca8-9114-62064506066a --><!-- end item 9598fe2c-f89a-46aa-bfd9-781794b47820 -->","subChapters":[]},{"id":"12cb560a-3537-5b16-b015-df0033bf5f0e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 7d07991c-2c21-47b9-8996-e587bc417221 --><h3>Contraindications and cautions</h3><!-- end field 7d07991c-2c21-47b9-8996-e587bc417221 -->","summary":"","htmlStringContent":"<!-- begin item 919b3b5f-e6f9-4542-a0d4-d7214c1d40c1 --><!-- begin field 8d5305c9-8130-4955-b65d-7d564d52e8c2 --><p><strong>Topical vitamin D preparations are contraindicated in people with:</strong></p><ul><li>Calcium metabolism disorders — these preparations may cause hypercalcaemia.</li><li>Severe liver and kidney disease.</li></ul><p><strong>Topical vitamin D preparations should be used with caution in people:</strong></p><ul><li>With erythrodermic or generalized pustular psoriasis — increased risk of hypercalcaemia.</li><li>Who are pregnant or breastfeeding — manufacturers advise to avoid in pregnancy unless essential. There is no information available regarding drug safety in breastfeeding. Seek specialist advice if needed.</li><li>Taking medications known to increase the serum calcium level, such as thiazide diuretics, or medications with pharmacological effects impacted by a change in calcium levels, such as digoxin.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">BNF 73, 2017</a>] </p><!-- end field 8d5305c9-8130-4955-b65d-7d564d52e8c2 --><!-- end item 919b3b5f-e6f9-4542-a0d4-d7214c1d40c1 -->","subChapters":[]},{"id":"0133ce5a-4eba-5360-8747-b4849effddfc","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 36d280e2-bb9f-4dcc-bd9a-1c3daaee06d6 --><h3>Adverse effects</h3><!-- end field 36d280e2-bb9f-4dcc-bd9a-1c3daaee06d6 -->","summary":"","htmlStringContent":"<!-- begin item ee7ce248-a928-4ba9-93ca-98194c9f801f --><!-- begin field 9a16eaa3-ac6f-443a-8aae-f37ecc204970 --><ul><li><strong>Local adverse effects </strong>include skin burning, dermatitis, erythema, itching, local skin reactions, and paraesthesia. Local adverse effects often reduce with time.<ul><li>If there is significant skin irritation, stop the treatment.</li><li>Advise the person to wash their hands thoroughly after application, to avoid transfer of the product to other parts of the body.</li></ul></li><li><strong>Systemic adverse effects </strong>are rare and include hypercalcemia, hypercalciuria, and parathyroid hormone suppression. These have been reported only in people using more than 100 g per week (greater than the recommended dose), in people who have kidney disease or impaired calcium metabolism, and in people with generalized pustular or erythrodermic psoriasis.</li><li><strong>Photosensitivity </strong>has been reported.<ul><li>Advise the person to avoid excessive exposure to sunlight and sunlamps.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">BNF 73, 2017</a>] </p><!-- end field 9a16eaa3-ac6f-443a-8aae-f37ecc204970 --><!-- end item ee7ce248-a928-4ba9-93ca-98194c9f801f -->","subChapters":[]},{"id":"cd5d8c09-a920-5101-b649-0729a6ce1e4d","slug":"application","fullItemName":"Application","depth":3,"htmlHeader":"<!-- begin field f8c6d6c5-fdbc-4de4-bd6b-7dbbde050b7b --><h3>Application</h3><!-- end field f8c6d6c5-fdbc-4de4-bd6b-7dbbde050b7b -->","summary":"","htmlStringContent":"<!-- begin item 1b10558b-a3ec-4609-a22c-f95f42feffa3 --><!-- begin field a276cf3d-4f44-4f7a-9807-81812b90b19b --><p><strong>Advise the person not to exceed the maximum recommended weekly dose due to the increased risk of adverse effects such as hypercalcaemia.</strong></p><ul><li><strong>Calcipotriol</strong><ul><li>Calcipotriol cream, ointment, and gel — should be applied once or twice a day; to a maximum of 100 grams each week.</li><li>Calcipotriol scalp solution — should be applied twice a day; to a maximum of 60 mL each week.</li><li>If an ointment and scalp solution are used together, the maximum dose is calcipotriol 5 mg each week, for example:<ul><li>Cream or ointment 30 grams plus scalp solution 60 mL.</li><li>Cream or ointment 60 grams plus scalp solution 30 mL.</li></ul></li></ul></li><li><strong>Calcipotriol and betamethasone combination product</strong><ul><li>Calcipotriol combined with betamethasone ointment — should be applied once daily for 4 weeks.</li><li>Calcipotriol combined with betamethasone scalp gel — 1–4 g should be applied once daily for 4 weeks (4 g is about one teaspoonful).<ul><li>The total amount of calcipotriol-containing product(s) applied should not exceed a maximum of 30% of body surface area, or 15 grams daily, or 100 grams each week.</li></ul></li></ul></li><li><strong>Calcitriol</strong><ul><li>Calcitriol ointment — should be applied twice daily; to a maximum of 30 grams each day.</li></ul></li><li><strong>Tacalcitol</strong><ul><li>Tacalcitol ointment — should be applied once daily; to a maximum of 10 grams each day.</li><li>Tacalcitol lotion — should be applied once daily; to a maximum of 10 mL each day.<ul><li>The total amount of tacalcitol should not exceed 280 micrograms/week (for example 30 mL of lotion plus 40 g of ointment).</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">BNF 73, 2017</a>]</p><!-- end field a276cf3d-4f44-4f7a-9807-81812b90b19b --><!-- end item 1b10558b-a3ec-4609-a22c-f95f42feffa3 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}